TAM (Treatments and Medicines) NHS Highland
Important: Therapy notes
MHRA advice: Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy (January 2020) (www.gov.uk).
MHRA advice: Ondansetron for intravenous use: posology in patients age 65 years or older (December 2014) (www.gov.uk).
MHRA advice: Ondansetron for intravenous use: dose-dependent QT interval prolongation (December 2014) (www.gov.uk).
MHRA advice: Ondansetron (Zofran): important new intravenous dose restriction (December 2014) (www.gov.uk).
- In oncology, see Guidelines for the management of chemotherapy-induced nausea and vomiting in adult patients.
Important: Formulation and dosage details
Formulation:
Tablets 4mg, 8mg
Dosage:
Prevention of post-operative nausea and vomiting, by mouth, 16mg 1 hour before anaesthesia or 8mg 1 hour before anaesthesia followed by a further 2 doses of 8mg every 8 hours.
Important: Formulation and dosage details
Formulation:
Oral lyophilisates 4mg, 8mg
Dosage:
Prevention of post-operative nausea and vomiting, by mouth, 16mg 1 hour before anaesthesia or 8mg 1 hour before anaesthesia followed by a further 2 doses of 8mg every 8 hours.
Notes:
Oral lyophilisates are useful in primary care for the immediate treatment of nausea and vomiting; place on the tongue, allow to disperse and swallow. Change to non-dispersible formulations at the earliest opportunity.
Important: Formulation and dosage details
Formulation:
Oral solution (sugar-free) 4mg/5mL
Dosage:
Prevention of post-operative nausea and vomiting, by mouth, 16mg 1 hour before anaesthesia or 8mg 1 hour before anaesthesia followed by a further 2 doses of 8mg every 8 hours.
Important: Formulation and dosage details
Formulation:
Injection 4mg/2mL, 8mg/4mL
Dosage:
Treatment of post-operative nausea and vomiting, by intramuscularor slow intravenous injection, 4mg.